DARWIN EU® continues expanding its capacity to deliver real-world data studies
Submitted by Anonymous (not verified) on 6 March 2024 - 14:00
DARWIN EU® continues expanding its capacity to deliver real-world data studies
Human medicines European public assessment report (EPAR): Cholib, fenofibrate,simvastatin, Date of authorisation: 26/08/2013, Revision: 17, Status: Authorised
Submitted by Anonymous (not verified) on 6 March 2024 - 11:32
Human medicines European public assessment report (EPAR): Cholib, fenofibrate,simvastatin, Date of authorisation: 26/08/2013, Revision: 17, Status: Authorised
List of signals discussed at PRAC since September 2012
Submitted by Anonymous (not verified) on 6 March 2024 - 10:54
List of signals discussed at PRAC since September 2012
PRAC recommendations on signals adopted at the 5-8 February 2024 PRAC meeting
Submitted by Anonymous (not verified) on 6 March 2024 - 10:49
PRAC recommendations on signals adopted at the 5-8 February 2024 PRAC meeting
Herbal medicinal product: Silybi mariani fructusArray, F: Assessment finalised
Submitted by Anonymous (not verified) on 5 March 2024 - 16:06
Herbal medicinal product: Silybi mariani fructusArray, F: Assessment finalised
Minutes of the PRAC meeting 8-11 January 2024
Submitted by Anonymous (not verified) on 5 March 2024 - 15:42
Minutes of the PRAC meeting 8-11 January 2024
CHMP rapporteurs' assessment report for paediatric studies submitted in accordance with Article 46
Submitted by Anonymous (not verified) on 5 March 2024 - 15:10
CHMP rapporteurs' assessment report for paediatric studies submitted in accordance with Article 46
Templates for assessors
Submitted by Anonymous (not verified) on 5 March 2024 - 15:10
Templates for assessors
Assessment report for post-authorisation measures (PAMs)
Submitted by Anonymous (not verified) on 5 March 2024 - 15:09
Assessment report for post-authorisation measures (PAMs)
Human medicines European public assessment report (EPAR): Ameluz, 5-aminolevulinic acid hydrochloride, Date of authorisation: 13/12/2011, Revision: 21, Status: Authorised
Submitted by Anonymous (not verified) on 5 March 2024 - 14:23
Human medicines European public assessment report (EPAR): Ameluz, 5-aminolevulinic acid hydrochloride, Date of authorisation: 13/12/2011, Revision: 21, Status: Authorised